| Drug Name |
Glutamine |
| Drug ID |
BADD_D01029 |
| Description |
A non-essential amino acid present abundantly throughout the body and is involved in many metabolic processes. It is synthesized from glutamic acid and ammonia. It is the principal carrier of nitrogen in the body and is an important energy source for many cells. An oral formulation of L-glutamine was approved by the FDA in July 2017 for use in sickle cell disease [L892]. This oral formulation is marketed under the tradename Endari by Emmaus Medical. |
| Indications and Usage |
Used for nutritional supplementation, also for treating dietary shortage or imbalance.
Used to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older [FDA Label]. |
| Marketing Status |
approved; investigational; nutraceutical |
| ATC Code |
A16AA03 |
| DrugBank ID |
DB00130
|
| KEGG ID |
D00015
|
| MeSH ID |
D005973
|
| PubChem ID |
5961
|
| TTD Drug ID |
D01JIA
|
| NDC Product Code |
58159-080; 42457-420; 51552-0285 |
| UNII |
0RH81L854J
|
| Synonyms |
Glutamine | L-Glutamine | L Glutamine | D-Glutamine | D Glutamine |
